B.M.P. PHARMA TRAD (BMP) fair value: what the stock is really worth
As of Oct 27, 2026: fair value (intrinsic value) of B.M.P. PHARMA TRAD stock €8.03, price €6.40, upside +25.5%, quality 79 out of 100. Rating: undervalued. Calculated from audited financials with 8 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range €0.5451 – €9.80 · fair‑value band €6.02 – €10.04 · the €6.40 price screens below the €8.03 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow B.M.P. PHARMA TRAD in your weekly email
Every Wednesday you see whether B.M.P. PHARMA TRAD is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
B.M.P. PHARMA TRAD (BMP) currently trades at €6.40, while our model-based Fair Value estimate is €8.03, implying the stock looks roughly 20% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of €9.77 per share, and 5 of the 8 models we run sit above the €6.40 price.
Bear case: the Asset-Based group reads lowest at €0.8200, and 3 of the 8 models stay below the price. Data coverage for this calculation is low.
Scenario range: €6.02 (bear) to €10.04 (bull), the price of €6.40 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 79/100 (high quality), in the Industrials sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
B.M.P. PHARMA TRAD reported revenue of €2.3K in FY2025 versus €4.5K in FY2021, a compound −15.1%/yr. Reported net income was €2.5M in FY2025, compounding −1.3%/yr from FY2021.
Key figures
Market cap €33.6M Micro · P/E ratio 9.3 · EPS (TTM) €0.6900 · Return on equity 27.8% · Return on assets (EBIT) −11.4% (5-year average) · Operating margin −99,546% · Revenue (TTM) €1.5K · Revenue growth (YoY) −60.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 90 out of 100 (low confidence).
What moves the price
The share trades about 35% below its 52-week high and 49% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Industrials peers we cover trades at −31% fair-value upside, at 25%, BMP screens cheaper than that median.
Fair Value models
Bear€6.02Fair Value €8.03Bull€10.04
Price €6.40 · Upside +25.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€0.5917 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.66/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+44.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.3%
Start year 2020 (pandemic). Over 10 years: −13.6% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.1%
’13
’15
’16
’17
’18
’19
’20
’21
’22
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+51.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+51.6%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−69,300% → −54,823%
⚠ Revenue per share shrinking 1.4%/yr over ~6Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Building Products & Equipment · 255 stocks
Beats the industry median on 5/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score79 · Top 25%
Fair Value upside+25.5% · Above median
Profitability
Return on equity (12 months)27.8% · Top 25%
Return on assets19.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)−60.8% · Bottom 25%
Dividend yield (12 months)0.0% · Bottom 25%
Valuation Multiplesvs Building Products & Equipment median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is B.M.P. PHARMA TRAD (BMP) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of €8.03 versus the last price from Oct 27, 2026 of €6.40, about +25% upside (undervalued).
What is the fair value of BMP?
Our model-based fair value for B.M.P. PHARMA TRAD is €8.03 (as of Nov 9, 2026), built from audited fundamentals. Last price (from Oct 27, 2026): €6.40.
What is the quality score of BMP?
B.M.P. PHARMA TRAD has a Quality Score of 79/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for B.M.P. PHARMA TRAD (BMP)?
Our model-based price target is the fair value of €8.03 (as of Nov 9, 2026) from 8 valuation models. Cautious scenario €6.02, optimistic scenario €10.04. It is a calculation from audited fundamentals, not an analyst target.
What is the B.M.P. PHARMA TRAD stock forecast for 2026?
Our models put fair value at €8.03, about +25% upside versus the last price from Oct 27, 2026 of €6.40 (undervalued). Cautious scenario €6.02, optimistic scenario €10.04. The calculation is refreshed regularly with new filings.
What is the revenue of B.M.P. PHARMA TRAD (BMP)?
B.M.P. PHARMA TRAD reported trailing-twelve-month revenue of about €1.5K (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of B.M.P. PHARMA TRAD (BMP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For B.M.P. PHARMA TRAD it is €8.03 per share (as of Nov 9, 2026), against a price of €6.40. It is the blended result of 8 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is B.M.P. PHARMA TRAD stock overvalued or undervalued in 2026?
As of Nov 9, 2026, BMP trades below its calculated fair value: price €6.40, fair value €8.03, a gap of about +25% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BMP?
No. The price is what the market pays today (€6.40); the fair value is what the company's own numbers justify (€8.03). For B.M.P. PHARMA TRAD the two are €1.63 per share apart. That gap is exactly why we show both numbers side by side.
How much is B.M.P. PHARMA TRAD worth?
The market values B.M.P. PHARMA TRAD at about €33.6M (market capitalisation, as of Nov 9, 2026). Per share that is €6.40; our models calculate a fair value of €8.03 per share.
What do the bullish and bearish scenarios say about BMP?
Our models span a range for B.M.P. PHARMA TRAD: cautious scenario €6.02, base €8.03, optimistic €10.04 per share (as of Nov 9, 2026, price €6.40). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BMP?
B.M.P. PHARMA TRAD trades at a price-to-earnings ratio of 9.3 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €8.03 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2017 to 2025), reported earnings: 10.7. Other multiples: P/B 3.8.
How solid is the balance sheet of B.M.P. PHARMA TRAD (BMP)?
Balance-sheet figures for B.M.P. PHARMA TRAD (as of Nov 9, 2026): return on equity 27.8%. They feed the Quality Score of 79/100, which measures business quality independently of the share price.
How far is BMP from its 52-week high?
B.M.P. PHARMA TRAD trades at €6.40, about 35% below its 52-week high of €9.80 and 49% above the low of €4.31 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of €8.03 is for.
Which stocks are comparable to B.M.P. PHARMA TRAD?
From the same area (Industrials) we also value Johnson Controls International plc, Trane Technologies plc, Carrier Global Corporation, Compagnie de Saint-Gobain S.A, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is B.M.P. PHARMA TRAD stock attractive at the current price?
The data as of Nov 9, 2026: price €6.40, calculated fair value €8.03 (+25%), Quality Score 79/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BMP calculated?
We run B.M.P. PHARMA TRAD through 8 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €8.03 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. B.M.P. PHARMA TRAD currently trades 20% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of B.M.P. PHARMA TRAD (BMP)?
The latest price we hold is from Oct 27, 2026 and stands at €6.40. Our model-based fair value is €8.03, about +25% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with B.M.P. PHARMA TRAD right now?
The rarer combination: high quality (79/100) AND below fair value. That earns a closer look rather than a quick verdict. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of B.M.P. PHARMA TRAD
How large is the market capitalisation of B.M.P. PHARMA TRAD (BMP)?
The market capitalisation of B.M.P. PHARMA TRAD is €33.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of B.M.P. PHARMA TRAD (BMP)?
Earnings per share at B.M.P. PHARMA TRAD are €0.6900 (price ÷ EPS = P/E 9.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of B.M.P. PHARMA TRAD (BMP)?
The return on equity (ROE) of B.M.P. PHARMA TRAD is 27.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of B.M.P. PHARMA TRAD (BMP)?
On an EBIT basis the return on assets of B.M.P. PHARMA TRAD is −11.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of B.M.P. PHARMA TRAD (BMP)?
The operating margin of B.M.P. PHARMA TRAD is −99,546% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at B.M.P. PHARMA TRAD (BMP)?
Revenue at B.M.P. PHARMA TRAD is growing −60.8% versus a year earlier (3y avg +12.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at B.M.P. PHARMA TRAD (BMP)?
Earnings per share at B.M.P. PHARMA TRAD are growing −55.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does B.M.P. PHARMA TRAD (BMP) carry?
The net debt of B.M.P. PHARMA TRAD is €126K (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch B.M.P. PHARMA TRAD in the live analysis
One click puts B.M.P. PHARMA TRAD on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026